Articles on diabetes drugs from NPS RADARArticles on diabetes drugs from NPS RADAR

Title Content Type Date Description
Another dipeptidyl peptidase-4 inhibitor (‘gliptin’) for add-on therapy in type 2 diabetes mellitus Professional publication - NPS RADAR - Brief item 2012-03-01 00:00:00 Another gliptin for treating type 2 diabetes, linagliptin, has been added to the Pharmaceutical Benefits Schedule.
Pioglitazone and bladder cancer: new safety advice Professional publication - NPS RADAR - Brief item 2011-08-16 00:00:09 Regulatory bodies have advised that taking pioglitazone for more than 12 months may increase the risk of bladder cancer.
Rosiglitazone (Avandia) and rosiglitazone with metformin (Avandamet): streamlined authority removed Professional publication - NPS RADAR - Brief item 2011-07-01 00:00:00 Due to continuing safety concerns, rosiglitazone can no longer be prescribed under a streamlined authority.
Sitagliptin, vildagliptin and saxagliptin — dipeptidyl peptidase-4 inhibitors (‘gliptins’) for add-on therapy in type 2 diabetes mellitus Professional publication - NPS RADAR - Review 2011-07-01 00:00:00 DPP-4 inhibitors (‘gliptins’) are a recently introduced class of oral drugs for improving glycaemic control in patients with type 2 diabetes mellitus. They are approved as add-on therapy in combination with either metformin or a sulfonylurea in patients poorly controlled with metformin, a sulfonylurea or a thiazolidinedione. The RADAR article on gliptins has been updated to reflect the listing of another gliptin. Saxagliptin was added to the PBS on 1 June 2011.
Exenatide (Byetta) for type 2 diabetes mellitus Professional publication - NPS RADAR - Review 2010-11-15 00:00:00 Exenatide has been listed on the PBS for dual therapy in combination with either metformin or a sulfonylurea for people with type 2 diabetes whose glycated haemoglobin (HbA1c) is > 7% despite treatment with metformin or a sulfonylurea, and for whom combination therapy with metformin and a sulfonylurea is contraindicated or not tolerated.
Exenatide (Byetta): first in another new class of diabetes drugs Professional publication - NPS RADAR - Brief item 2010-08-01 00:00:00 Exenatide is an injectable drug in the new class of incretin mimetics, PBS listed from 1 August 2010 for type 2 diabetes.
Postmarketing reports of acute pancreatitis with sitagliptin products (Janumet, Januvia) Professional publication - NPS RADAR - Brief item 2010-04-01 00:00:00 Cases of acute pancreatitis have been reported with sitagliptin and sitagliptin with metformin. Be alert for signs and symptoms in patients taking these products, and use cautiously in people with a history of pancreatitis.
Sitagliptin with metformin (Janumet) fixed-dose combination tablets PBS listed for type 2 diabetes mellitus Professional publication - NPS RADAR - Brief item 2009-08-01 00:00:00 Sitagliptin with metformin tablets (Janumet) in fixed-dose combinations of 50/500 mg, 50/850 mg and 50/1000 mg are available on the PBS as of 1 August 2009.
Prescribing for up to 12 months allowed for some medicines for some people with chronic conditions Professional publication - NPS RADAR - Brief item 2008-12-01 00:00:00 Repeat prescriptions may be written for up to 12 months for some medicines prescribed for some people with chronic conditions.
Rosiglitazone (Avandia) and rosiglitazone with metformin (Avandamet) for type 2 diabetes mellitus Professional publication - NPS RADAR - Review 2008-12-01 00:00:00 Rosiglitazone improves glycaemic control but there is a lack of evidence that it improves diabetes–related clinical complications and mortality. Rosiglitazone is no longer indicated in combination with insulin or for triple oral therapy in combination with metformin and a sulfonylurea. Rosiglitazone is a third-line choice. It may still be considered as part of dual therapy when either metformin or a sulfonylurea is contraindicated or not tolerated. Insulin should also be considered instead of rosiglitazone in these scenarios. Do not use rosiglitazone in people with heart failure or a history of heart failure.
Pioglitazone (Actos) for type 2 diabetes mellitus Professional publication - NPS RADAR - Review 2008-04-01 00:00:00 Information on use of pioglitazone (Actos) for type 2 diabetes mellitus, including safety and dosing issues.
Another ultra-short-acting insulin PBS listed: insulin glulisine Professional publication - NPS RADAR - Brief item 2007-12-01 00:00:00 Insulin glulisine (Apidra) is the third ultra-short-acting insulin analogue listed on the PBS, the others being insulin lispro and insulin aspart, for treatment of type 1 and type 2 diabetes.
Rosiglitazone and cardiovascular risk - NPS fact sheet Professional publication - NPS RADAR - Brief item 2007-08-01 00:00:00 NPS has released a fact sheet discussing a recent meta-analysis that has raised concerns about a potential increase in cardiovascular risk among patients treated with rosiglitazone.
Insulin glargine (Lantus) for type 1 and 2 diabetes mellitus Professional publication - NPS RADAR - Review 2006-12-01 00:00:00 Reviews use of insulin glargine for diabetes mellitus, including comparison with isophane insulin and risk of hypoglycemia.
Rosiglitazone with metformin combination tablets (Avandamet) listed on the PBS. Professional publication - NPS RADAR - Brief item 2006-12-01 00:00:00 Rosiglitazone with metformin in a fixed-dose combination tablet (Avandamet) was listed on the PBS as a third-line choice, after metformin and/or a sulfonylurea.
Pioglitazone (Actos) and rosiglitazone (Avandia) authority wording changed Professional publication - NPS RADAR - Brief item 2006-08-01 00:00:00 The wording of the PBS requirements for pioglitazone (Actos) and rosiglitazone (Avandia) changed on 1 August 2006. The changes are intended to simplify the listings, and there are no changes to the authority requirements.
Metformin/glibenclamide (Glucovance) for type 2 diabetes mellitus Professional publication - NPS RADAR - Review 2005-12-01 00:00:00 Reviews use of metformin/glibenclamide combination tablets for type 2 diabetes mellitus, including comparison with co-administered drugs and risk of hypoglycaemia.

NPS RADAR: independent, evidence-based assessment of new drugs, new PBS listings and the latest research for doctors, pharmacists and other health professionals.

RSS FeedRSS feed

Date published: 2009-10-28 00:00:00

Reasonable care is taken to provide accurate information at the date of creation. This information is not intended as a substitute for medical advice from a qualified health professional. Health professionals should rely on their own expertise and enquiries when providing medical advice or treatment. Where permitted by law, NPS disclaims all liability (including for negligence) for any loss, damage or injury resulting from reliance on or use of this information. Read our full disclaimer.

References to brands should not be taken as an endorsement by NPS.